Pro Athlete Benefits From Co.'s Wound Treatment Device
Source: Streetwise Reports  (7/22/22)
Shares of SANUWAVE Health Inc. traded 12% higher after the company reported it successfully treated legendary football player Jim McMahon Jr. with its ENERGY FIRST system. More >

Small Biomedical Device Co. Is Ready to Take a Big Step Into Success
Source: Tim Weintraut  (6/8/22)
After weathering some major setbacks, PetVivo Holdings Inc. is stepping it up. With their new product for osteoarthritis and the team's perseverance, they may soon show themselves as a diamond in the rough. More >

Biopharma Co. Posts Positive Data in Ph. 1 Cancer Trials
Source: Streetwise Reports  (4/25/22)
Nkarta Inc. shares traded over 120% higher after the company reported positive dosing data from two separate Phase 1 clinical trials evaluating the use of natural killer cell therapies to target r/r acute myeloid leukemia and myelodysplastic syndrome and r/r B cell malignancies. More >

FDA Grants RMAT Status for T-Cell Therapy for Six Viruses
Source: Streetwise Reports  (4/20/22)
Shares of AlloVir Inc. traded 18% higher after the firm reported that the U.S. FDA awarded Regenerative Medicine Advanced Therapy designation to its posoleucel for use in preventing life-threatening infections from six viruses in allogeneic hematopoietic cell transplant patients. More >

Regenerative Medicine Co. Posts 38% Sales Gain in 2021
  (3/2/22)
Organogenesis Holdings Inc. shares traded 23% higher after the company reported FY/21 financial results that included a 46% YoY increase in revenue from its Advanced Wound Care products sales. More >

Cellular Therapy Co. Earns Rare Pediatric Disease Designation for Infant Congenital Heart Treatment
Source: Streetwise Reports  (11/20/21)
Shares of Longeveron Inc. traded 50% higher after the company reported that the U.S. FDA approved its Lomecel-B for Rare Pediatric Disease Designation to treat a rare and life-threatening defect in infants called Hypoplastic Left Heart Syndrome. More >

Alector Partners with GSK to Develop Monoclonal Antibodies for Neurodegenerative Diseases
Source: Streetwise Reports  (7/2/21)
Alector Inc. shares traded 59% higher after the company announced it entered into a global collaboration agreement with GlaxoSmithKline to develop and advance two first-in-class, clinical stage monoclonal antibodies for treating neurodegenerative diseases including frontotemporal dementia, amyotrophic lateral sclerosis, Parkinson's and Alzheimer's. More >

Intellia Shares Rise 49% on 'Landmark' Interim Results in Phase 1 ATTR Amyloidosis Trial
Source: Streetwise Reports  (6/28/21)
Intellia Therapeutics soared to a new 52-week high after the firm reported that in a Phase 1 clinical study with partner Regeneron, it had achieved "landmark clinical data" that demonstrated deep reduction in disease-causing protein after a single infusion of NTLA-2001, an investigational CRISPR therapy for transthyretin (ATTR) amyloidosis.

More >

Twist Bioscience Shares Wind Higher After Firm Posts 62% YoY Increase in Q2 Revenue
Source: Streetwise Reports  (5/7/21)
Shares of Twist Bioscience Corp. traded 14% higher after the firm reported that orders in Q2/21 grew by 69% year-over-year and that it is raising its FY/21 revenue guidance to $121–129 million. More >

CryoLife Shares Trade 18% Higher on Q1 Financial Results
Source: Streetwise Reports  (4/30/21)
Shares of CryoLife Inc. set a new 52-week high intraday price after the company reported that total revenues in Q1/21 increased by 7% YoY to $71.1 million. More >

Regenerative Medicine Firm Reports Positive Chronic Lower Back Pain Trial Results
Source: Streetwise Reports  (2/17/21)
New study data and next steps for Mesoblast's MPC-06-ID are presented in a Dawson James Securities report. More >

Analyst: Differences Between Two Possible COVID-19 Therapies Noteworthy
Source: Streetwise Reports  (12/23/20)
The factors that set Athersys' stem cell product MultiStem apart from a competitor's therapeutic are provided in a Dawson James Securities report. More >

Organogenesis Shares Rise 20% on Q3 Net Revenue Growth and FY Guidance
Source: Streetwise Reports  (10/15/20)
Shares of Organogenesis Holdings traded higher after the company reported preliminary Q3/20 financial results demonstrating a 55% increase in year-over-year revenue. More >

Phase 3 COVID-19 Study of Firm's Stem Cell Product Exceeds 50% Enrollment
Source: Streetwise Reports  (10/14/20)
The study design and goals and Mesoblast's next steps are reviewed in a Dawson James Securities report. More >

Regenerative Medicine Firm Reports Early Results from COVID-19 Trials
Source: Streetwise Reports  (6/17/20)
Pluristem Therapeutics' coronavirus clinical studies and financing are discussed in a Dawson James report. More >

Mesoblast Shares Soar 120% After Reporting 83% Survival Rate in COVID-19 Patients with ARDS
Source: Streetwise Reports  (4/24/20)
Shares of Mesoblast more than doubled and set a new 52-week high price after the company reported that it achieved a 83% survival rate in New York ventilator-dependent COVID-19 patients with moderate to severe acute respiratory distress syndrome who were treated with its allogeneic cell therapy remestemcel-L. More >

Biotech to Test Stem Cell Product in COVID-19-Caused Acute Respiratory Distress
Source: Streetwise Reports  (4/15/20)
A description of Mesoblast's multi-site clinical trial and possible implication for the therapeutic are provided in an H.C. Wainwright & Co. report. More >

Three COVID-19 Patients Treated with PLX Cells
Source: Streetwise Reports  (4/1/20)
Two programs, one new and the other ongoing, involving Pluristem Therapeutics' regenerative products are reviewed in a Dawson James report. More >

'Stay Tuned for Data' from Regenerative Medicine Firm with 'Blockbuster Opportunity'
Source: Streetwise Reports  (1/31/20)
The compelling aspects of this life sciences story are presented in a Dawson James report. More >

Proteostasis Therapeutics Reports Positive Results from European Cystic Fibrosis Research
Source: Streetwise Reports  (12/11/19)
Proteostasis Therapeutics' shares traded higher today after the company reported positive results in its European Cystic Fibrosis study of organoids grown from human stem cells. The firm believes the ongoing ex-vivo study supports initiation of a human clinical trial in mid-2020, and potential for a Marketing Authorization Application in 2021. More >

Regenerative Medicine Firm Advances Multifaceted Pipeline
Source: Streetwise Reports  (11/26/19)
The company continues advancing its cell therapies and medical device. More >

IVERIC bio Shares Double After Announcing Phase 2b AMD Topline Data
Source: Streetwise Reports  (10/28/19)
Shares of IVERIC bio opened nearly 100% higher today after reporting that it successfully met its primary endpoint in its Phase 2b age-related macular degeneration study for Zimura. More >

Fiscal Year 'Reads Well' for Regenerative Medicine Company
Source: Streetwise Reports  (9/4/19)
The firm's final quarter and full-year results are reviewed in a Ladenburg Thalmann report. More >

Trial Milestone Reached; U.K.-Based Biopharma Gets $15 Million
Source: Streetwise Reports  (5/8/19)
The first patient has been treated in the second cohort of a Phase 2 study of a gene therapy targeting Parkinson's disease, explained an H.C. Wainwright & Co. report. More >

First Cobalt Corp., Oversold, Poised for Rebound This Year?
Source: Peter Epstein for Streetwise Reports  (4/1/19)
Peter Epstein of Epstein Research discusses the market for cobalt and profiles one company whose shares he believes could be at an attractive entry point. More >